APTX Aptinyx Inc.

5.88
+0.16  (+3%)
Previous Close 5.72
Open 5.74
Price To Book 1.22
Market Cap 196964383
Shares 33,497,344
Volume 767,076
Short Ratio
Av. Daily Volume 314,318

SEC filingsSee all SEC filings

  1. 8-K - Current report 19537679
  2. 8-K - Current report 19528291
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181178659
  4. 8-K - Current report 181175142
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181018126

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due 1H 2019.
NYX-458
Parkinson’s Disease Cognitive Impairment (healthy volunteers)
Phase 2 full data due 1H 2019.
NYX-2925
Fibromyalgia
Phase 2 data released January 16, 2019 - primary endpoint not met.
NYX-2925
Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Phase 2 data due 2H 2019.
NYX-783
Post-traumatic stress disorder (PTSD)

Latest News

  1. The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
  2. Biotech Play Aptinyx Tanks After Drug Trial Fails
  3. Why Ford Motor, Snap, and Aptinyx Slumped Today
  4. Here's Why Aptinyx Got Crushed Today
  5. Aptinyx stock falls 67% after phase 2 trial fails to meet primary endpoint
  6. Aptinyx Reports Top-line Results from Phase 2 Clinical Study of NYX-2925 in Painful Diabetic Peripheral Neuropathy
  7. Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference
  8. Should You Take Comfort From Insider Transactions At Aptinyx Inc. (NASDAQ:APTX)?
  9. Aptinyx to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
  10. Aptinyx Reports Positive Data from Interim Analysis of Exploratory Study of NYX-2925 in Subjects with Fibromyalgia
  11. Factors of Influence in 2018, Key Indicators and Opportunity within Atlantic American, Titan Medical, Adial Pharmaceuticals, Aptinyx, Sotherly Hotels, and Titan Pharmaceuticals — New Research Emphasizes Economic Growth
  12. Aptinyx Reports Third Quarter 2018 Financial Results and Business Highlights
  13. Aptinyx Completes Enrollment in Phase 2 Study of NYX-2925 for Painful Diabetic Peripheral Neuropathy
  14. Aptinyx to Present Preclinical Data on Novel NMDA Receptor Modulators for Pain and Cognition at the 48th Annual Meeting of the Society for Neuroscience